Evaluation of the Pharmacokinetics of Prana P1 Capsules

Inclusion Criteria: * Males between 18 and 55 years. * Body weight with a Body Mass Index (BMI) range of 18.5 to 27.0 \[or weight within 15% of ideal weight for participant's height and frame * Healthy, with normal findings in the physical examination and vital signs (BP between 100-140/60-90 mmHg, Heart rate (HR) between 60 to 90 beats/min, respiration between 12 to 24 breaths/min) and no clinically-significant findings in a 12-lead ECG. * No clinical laboratory values outside of the laboratory normal reference range, unless the investigator determines them to be not clinically significant. * Negative for hepatitis B surface antigen, hepatitis C antibody, HIV --Willing and able to communicate well with the investigator and clinic staff, comply with the study procedure and schedule, and provide written informed consent. * Able to understand the requirements of the study and sign Informed Consent. Exclusion Criteria: * Current major Axis I psychiatric disorder for which the participant is currently receiving treatment or which would make study compliance an issue. * Any condition or therapy that, in the opinion of the investigator, may be significantly worsened by the exposure to marijuana. * Acute disease at the time of enrolment (i.e., presence of a moderate or severe illness or infection with or without a fever). * Febrile illness (oral temperature \>37.6° C at the time of drug administration). * Unstable chronic illnesses. * Chronic liver, renal or inflammatory bowel disease or collagen vascular disease. * Clinically significant elevation of Alanine transaminase(ALT) and/or Aspartate transaminase (AST). * Active neurological disorder. * Clinically significant uncontrolled illness or clinically significant surgery within 4 weeks prior to administration of study drug. * Cancer within the previous 5 years, other than squamous cell or basal cell carcinoma of the skin. * Difficulty to swallow study medication. * Smoking more than 25 cigarettes per day. * History of any clinical laboratory abnormality deemed significant by the Principal Investigator. * History of serious adverse reaction or hypersensitivity to any drug. * Bleeding tendency resulting from disease or medication rendering blood collection or the injection itself unsafe (use of antiplatelet agents is allowed). * Coagulation disorders or receiving anticoagulant therapy. * Inability to tolerate abstinence from caffeine for 24 hours prior to and during the study treatment phase. * Consumption of alcohol within 24 hours prior to dosing and during the treatment phase. * History of significant alcohol or drug abuse within one year prior to the screening visit * Chronic use (i.e., ≥3 days per week) of marijuana based products within 3 months prior to the screening visit. * Use of hard recreational drugs (such as cocaine, phencyclidine \[PCP\] and crack) within one year prior to the screening visit. * Donation of plasma (500 mL) within 7 days prior to drug administration * Any known or suspected allergy to any constituent of marijuana. * Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Sub-Investigators, contraindicates the participant 's participation in this study. * Use of any investigational or non-registered drug or participation in an investigational study within 30 days prior to administration of study drug.